Related Experiment Video

Updated: Jun 13, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

[Endothelial dysfunction: role of vasodilating betablockers in hypertension and chronic heart failure]

C Thuillez1

  • 1Service de Pharmacologie, Institut de Biologie Clinique, INSERM U644, Université de Rouen CHU de Rouen, France. christian.thuillez@chu-rouen.fr <christian.thuillez@chu-rouen.fr>

Annales De Cardiologie Et D'Angeiologie
|April 20, 2010
PubMed

Insights

Beta blockers for hypertension and heart failure vary. Vasodilating beta blockers offer benefits over non-vasodilating ones, improving arterial health and reducing heart workload. Third-generation agents provide antioxidant and endothelial protection.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Internal Medicine

Context:

  • Beta-blocking agents are widely used for hypertension and heart failure.
  • Pharmacological heterogeneity exists within beta blockers.
  • Non-vasodilating beta blockers may have adverse effects on vascular and metabolic parameters.

Purpose:

  • To compare the effects of different classes of beta blockers on cardiovascular parameters.
  • To highlight the benefits of vasodilating beta blockers and third-generation agents.

Summary:

  • Non-vasodilating beta blockers (e.g., propranolol, atenolol, metoprolol) do not improve intima-media thickness or arterial rigidity in hypertensive patients and may induce diabetes.
  • Vasodilating beta blockers demonstrate beneficial effects on these vascular parameters.
  • Third-generation beta blockers (celiprolol, carvedilol, nebivolol) possess antioxidant properties, offering endothelial protection and avoiding deleterious metabolic effects, crucial for target organ protection in hypertensive patients.

Impact:

  • Vasodilating and third-generation beta blockers represent an advancement in cardiovascular therapy.
  • These agents may offer improved long-term outcomes and target organ protection in hypertensive patients.
  • Understanding beta blocker subclasses is vital for optimizing treatment strategies in cardiovascular disease.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...